factual

Three-Quarters of New Patents Are Old Drugs

More than three-quarters (78%) of drugs associated with new patents are not new drugs coming to market but existing ones, because companies begin with patent or non-patent exclusivity monopolies and repeatedly extend protection by piling on secondary patents, channeling innovation into recycling and repurposing rather than inventing genuinely new drugs.

factualpending

Speaker

Robin Feldman

Evidence Quote

“instead of innovation, we are seeing secondary patents piled onto new drugs over and over again... This is channeling innovation in a less productive direction.”

Source

Robin Feldman on Drugs, Money, and Secret Handshakes— EconTalk
Created: 6/13/2026, 12:12:41 AM

Your notes

Loading notes...